Smoking Cessation in People with HIV

Module References

  • Bell SK, Mena G, Dean J, et al. Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ attitudes. Drug Alcohol Depend. 2017;177:67-70.
  • Bell SK, Mena G, Dean J, et al. Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes. AIDS Care. 2019 Apr;31(4):436-442.
  • Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: Toward the implementation of cessation programs. ANRS CO3 Aquitaine cohort. AIDS Patient Care STDS. 2007;21(7):458-468.
  • Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers. A randomized clinical trial. JAMA Intern Med. 2018;178(5):622-631.
  • Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2000;160(20):3128-3134.
  • Burkhalter JE, Springer CM, Chhabra R, et al. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res. 2005;7(4):511-522.
  • Calvo M, Laguno M, Martinez M, & Martinez E. Effects of tobacco smoking on HIV-infected individuals. AIDS Review. 2015;17(1): 47-55.
  • Cropsey KL, Bean MC, Haynes L, et al. Delivery and implementation of an algorithm for smoking cessation treatment for people living with HIV and AIDS. AIDS Care. 2020;32(2)223-229.
  • Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev. 2009;21(3 Suppl):40-53.
  • Cui Q, Robinson L, Elston D, et al. Safety and tolerability of varenicline tartrate for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Pat Care STDs. 2012;26(1):12-19.
  • DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001;15(10):1281-1285.
  • De Socio GV, Ricci E, Maggi P, et al. Is it feasible to impact on smoking habits in HIV-infected patients? Mission impossible from the STOPHIV Project cohort. JAIDS. 2020. PMID: 31914000.
  • Encrenaz G, Rondeau BV, Bonnet F, et al. Determinants of smoking cessation attempts among HIV-infected patients from a hospital-based prospective cohort. Curr HIV Res. 2010;8(3):212-7.
  • Fiore M. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guidelines. Respir Care. 2000 Oct;45(10):1196-9.
  • Giles ML, Gartner C, Boyd MA. Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal? AIDS Res Ther. 2018;15(1):26. doi: 10.1186/s12981-018-0213-z.
  • Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006; 296:47-55. 
  • Gritz ER, Vidrine DJ, Lazev AB, et al. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6(1):71-77. 
  • Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727-34
  • Hsia, SL, Myers MG, Chen TC. Combination nicotine replacement therapy: strategies for initiation and tapering. Prev Med. 2017;97:45-49.
  • Horvath KJ, Eastman M, Prosser R, et al. Addressing smoking during medical visits: patients with human immunodeficiency virus. Am J Prev Med. 2012 Nov;43(5 Suppl 3):S214-21.
  • Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29-38.
  • Jorenby DE, Taylor Hays J, Rigotit NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA. 2006; 296:56-63. 
  • Kariuki W, Manuel JI, Kariuki N, et al. HIV and smoking: associated risks and prevention strategies. HIV AIDS (Auckl). 2016; 8: 17-36.
  • Keith A, Dong Y, Shuter J, et al.  Behavioral interventions for tobacco use in HIV-infected smokers: A meta-analysis. J Acquir Immune Defic Syndr. 2016 72(5):527-33.
  • Kwong J, Bouchard-Miller K. Smoking cessation for persons living with HIV: A review of currently available interventions. J Assoc Nurses AIDS Care. 2010;21(1):3-10.
  • Lazev A, Vidrine D, Arduino R, Gritz E. Increasing access to smoking cessation treatment in a low-income, HIV-positive population: the feasibility of using cellular telephones. Nicotine Tob Res. 2004;6(2): 281-286.
  • Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896-1903.
  • Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, et al. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2016;10:CD005231.
  • Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. Motivation and patch treatment for HIV+ smokers: A randomized controlled trial. Addiction. 2009;104(11):1891-1900.
  • Manuel JK, Lum PJ, Hengl NS, Sorensen JL. Smoking cessation interventions with female smokers living with HIV/AIDS: A randomized pilot study of motivational interviewing. AIDS Care. 2013;25(7):820-827. 
  • Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol. 2006; 70(3):801-805.
  • Moadel AB, Bernstein SL, Murmelstein RJ, et al. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. JAIDS. 2012;61(2):208-215.
  • Nansseu JR, Tounouga DN, Noubiap JJ, et al. Changes in smoking patterns after HIV diagnosis or antiretroviral treatment initiation: a global systematic review and meta-analysis. Infect Dis Poverty. 2020. 15;9(1):35. doi: 10.1186/s40249-020-00644-z.
  • Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577.
  • Reus VI, Smith BJ. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines. Int J Clin Pract. 2008;62(11):1753-1768.
  • Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav. 2012 Jan;36(1):75-85.
  • Shuter J, Kim RS, Durant S, et al. Long-term follow-up of smokers living with HIV after an intensive behavioral tobacco treatment intervention. J Acquir Immune Defic Syndr. 2020. Feb 14.  doi: 10.1097/QAI.0000000000002330. Online ahead of print.
  • Shuter J, Salmo LN, Shuter AD, et al. Provider beliefs and practices relating to tobacco use in patients living with HIV/AIDS: a national survey. AIDS Behav. 2012 Feb;16(2):288-94.
  • Slemmer JE, Martin RM, Damaj MI. Buproprion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295(1):321-7.
  • Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008; (1):CD000146.
  • Stead LF, Perera R, Bullen C. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146. 
  • Tornero C, Mafe C. Varenicline and antiretroviral therapy in patients with HIV. JAIDS. 2009;52(5):656.
  • US Preventive Services Task Force. Primary Care Interventions for Prevention and Cessation of Tobacco Use in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(16):1590-1598.
  • Vidrine DJ, Arduino RC, Gritz ER. Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS. Nicotine Tob Res. 2006;8 Suppl 1:S103-S108. 
  • Vidrine DJ, Marks RM, Arduino RC, Gritz ER. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2012;14(1):106-110. 
  • Westman E, Tomlin K, Rose J. Combining the nicotine inhaler and nicotine patch for smoking cessation. Am J Health Behav. 2000;24(2):114-119. 
  • Wewers ME, Needing JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. J Assoc Nurses AIDS Care. 2000;11(6):37-44. 
  • Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with E-cigarette Use or Vaping. February 25, 2020. Available at: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-d.... Accessed April 20, 2020.
  • Food and Drug Administration. [Accessed April 20, 2020] Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban. 2009. Retrieved from https://wayback.archiveit.org/7993/20170406005315/https://www.fda.gov/Dr... /ucm170906.htm.
  • NCT01800019. The Canadian HIV Quite Smoking Trial. Available at https://clinicaltrials.gov/ct2/show/NCT01800019. Accessed April 20, 2020.
  • Smokefree.gov. Available at: https://smokefree.gov/. Accessed April 25, 2020.
  • US Department of Health and Human Services.  The Health Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
  • US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services; 2008. Available at: https://www.ncbi.nlm.nih.gov/books/NBK63952/. Accessed April 15, 2020.

 

Thank you for visiting the AAHIVM Provider Education Center! 

In order to continue, we will need you to create a profile. This will help us keep track of your education activity and CME accreditations.

           NEW USERS CLICK HERE TO CREATE A PROFILE.           

ALREADY CREATED YOUR AAHIVM PROFILE? CLICK HERE TO SIGN IN.

Are you an AAHIVM member? If not, consider supporting the Academy and programs like these. Click here to become an Academy member.

 

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.